Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewsWire • 04/29/26
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlookBusiness Wire • 04/27/26
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026Business Wire • 04/16/26
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx PanelBusiness Wire • 04/14/26
Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell AnalysisBusiness Wire • 03/31/26
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB PreventionBusiness Wire • 03/19/26
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing SystemBusiness Wire • 03/10/26
Qiagen N.V. (QGEN) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
Qiagen N.V. (QGEN) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/09/26
Qiagen N.V. (QGEN) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/02/26
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell RecoveryBusiness Wire • 02/19/26
Qiagen (QGEN) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/05/26
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026Business Wire • 02/03/26